PMID- 11195181
OWN - NLM
STAT- MEDLINE
DCOM- 20010201
LR  - 20071115
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 52
IP  - 5
DP  - 2000 Sep-Oct
TI  - [Classification of acute leukemias according to the first latin-american 
      consensus conference for the immunophenotyping of leukemias].
PG  - 524-8
AB  - OBJECTIVE: To evaluate the recommendations of the First Latinamerican Consensus 
      Conference for the Immunophenotyping of Acute Leukemia in untreated patients with 
      de novo disease immunologically classified employing flow cytometry and an 
      extended panel of monoclonal antibodies. MATERIAL AND METHODS: In that conference 
      it was recommended the use of the following antibodies: cytoplasmic CD79a 
      (cCD79a) and CD19 to define B-progenitor acute lymphoblastic leukemia (B-ALL); 
      cCD3 and CD7 for T-cell ALL (T-ALL), and CD13, CD33 and myeloperoxidase (cMPO) 
      for acute myeloblastic leukemia (AML). We analyzed the expression of these 
      cellular antigens in 91 non-consecutive patients classified with the extended 
      panel as: B-ALL 28 cases; T-ALL 7; B-T-ALL 2; AML 47; and mixed-lineage acute 
      leukemia 7 cases. RESULTS: All 28 B-ALL cases were positive with each of the two 
      recommended antibodies cCD79a and CD19, whereas in 24 AML cases (the expression 
      of cCD79a was not assayed in 23 cases) and in 7 T-ALL patients both antigens were 
      absent. cCD3 and CD7 antigens were identified in 71% and 100% of T-ALL, 
      respectively. CD7 antigen was not detected in any of the 28 patients with B-ALL 
      but it was expressed in 6 of 47 AML cases, while none of 75 B-ALL and AML cases 
      were positive to cCD3. Forty nine percent of AML were positive for the three 
      recommended markers: cMPO, CD13 and CD33, and 51% of AML cases reacted with one 
      or two of these three monoclonal antibodies. Six out of 28 cases of B-ALL had 
      aberrant expression of myeloid antigen (CD33 in 3 cases and CD13 in 3 cases). 
      CONCLUSIONS: There was no difference in the definition of AL lineage between 
      employing the extended antibody panel and that recommended by the Latinamerican 
      consensus.
FAU - Piedras, J
AU  - Piedras J
AD  - Departamento de Hematologia y Oncologia, Laboratorio de Biologia Celular, 
      Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. 
      piedras@quetzal.innsz.mx
FAU - Barrales-Benitez, O
AU  - Barrales-Benitez O
FAU - Lopez-Karpovitch, X
AU  - Lopez-Karpovitch X
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Clasificacion de las leucemias agudas de acuerdo con el consenso de la primera 
      conferencia latinoamericana en la tipificacion inmunologica de las leucemias.
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la 
      Nutricion
JID - 9421552
SB  - IM
MH  - Acute Disease
MH  - Consensus Development Conferences as Topic
MH  - Humans
MH  - Immunophenotyping
MH  - Latin America
MH  - Leukemia/*classification/immunology
EDAT- 2001/02/24 12:00
MHDA- 2001/02/28 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
PST - ppublish
SO  - Rev Invest Clin. 2000 Sep-Oct;52(5):524-8.